AMPK and p53 help cells through lean times  by Thoreen, Carson C. & Sabatini, David M.
PreviewsAMPK and p53 help cells through lean times
Cells that encounter low nutrient conditions often respond by arresting cell division or becoming apoptotic. Recent work
by Jones and colleagues (Jones et al., 2005) reveals how the AMP-activated kinase mediates this process by phosphorylat-
ing and activating the tumor suppressor p53.Mammalian cells are highly sensitive to c
many forms of stress, including both en- A
tvironmental changes and internal dam-
age. A common consequence is either a t
freversible cell-cycle arrest or induction
of senescence or apoptosis. Although i
gmany stress-sensing pathways have
been well studied, those that connect c
metabolic stress to regulators of prolifer-
ation and survival are still poorly under- c
istood. In particular, there is no clear link
that explains the common observation c
cthat starvation for small molecule nutri-
ents causes most cells to arrest. In the t
tApril 29th issue of Molecular Cell, Jones
et al. describe how the AMP-activated t
Akinase (AMPK) connects glucose avail-
ability to the p53 pathway, a central reg- p
sulator of proliferation and survival (Jones
et al., 2005). This finding reveals how a b
2fundamental physiologic response is
surprisingly mediated by two well- s
cstudied pathways and sheds light on the
strategies that cells use to survive a
pperiods of nutrient deprivation. It also
suggests, more broadly, how defects in o
dthe cell’s metabolic machinery might in-
fluence the development of human dis- p
weases such as cancer.
AMPK is activated under energetically s
cstressful conditions and is often consid-
ered the cellular “fuel gauge” because of
aits role in sensing and modulating meta-
bolic processes. Although it is thought c
sto directly sense increases in the intra-
cellular AMP:ATP ratio, it is also regu- d
clated by the upstream tumor suppressor
LKB1(Carling, 2004). Given its role as a t
(metabolic sensor and previous work
linking pharmacological activation of a
tAMPK to cell-cycle arrest, Thompson
and colleagues suspected it might also 1
nfunction in starvation-induced arrest
(Imamura et al., 2001). Indeed, when i
tAMPK was inhibited by expression of a
dominant-negative mutant in mouse c
(embryonic fibroblasts (MEFs), mimick-
ing energy-rich conditions, these cells o
ono longer arrested when starved for glu-
cose. Likewise, MEFs transfected with a oCELL METABOLISM : MAY 2005 · VOL. 1 · COPonstitutively active mutant AMPK (CA- c
wMPK), or treated with the AMPK activa-
or AICAR, arrested at the G1/S transi- l
tion despite sufficient glucose. These
indings directly implicated AMPK as the w
tnitiator of cell-cycle arrest under low-
lucose conditions and suggested a t
Monnection to cell-cycle regulators.
The next step was to determine which S
uomponents downstream of AMPK were
nfluencing proliferation. An attractive g
landidate was the mTOR pathway, a
entral controller of cell growth and pro- p
oein synthesis whose activity is both nu-
rient sensitive and required for prolifera- a
mion (Bjornsti and Houghton, 2004).
MPK can suppress this pathway by A
ahosphorylating and activating the up-
tream negative regulator TSC2, possi- p
2ly arresting cells indirectly (Inoki et al.,
003). The authors tested this hypothe- n
tis by growing MEFs under low-glucose
onditions or in the presence of AICAR m
nnd then treating them with the drug ra-
amycin, a potent and specific inhibitor M
f mTOR. Rapamycin treatment still re-
uced cell growth, and the authors inter- p
sret this to mean that the mTOR path-
ay remains partially active under l
starvation conditions that cause cell-
ycle arrest. A
aIn a change of angle, the authors
sked whether AMPK might activate A
aomponents involved in the cellular re-
ponse to DNA damage, which also in- 1
auces cell-cycle arrest. DNA damage
aused by ionizing radiation activates c
hhe kinase ataxia telangiectasia mutated
ATM), which, in turn, phosphorylates a
pnd stabilizes the tumor suppressor and
ranscription factor p53 (Canman et al., t
p998). p53 is rapidly degraded under
ormal conditions but when stabilized p
onduces the expression of many genes
hat play key roles in cell-cycle arrest, w
nellular senescencem and apoptosis
Vogelstein et al., 2000). The importance t
tf this response is underscored by the
bservation that p53 is either mutated or t
vtherwise inactivated in most humanYRIGHT © 2005 ELSEVIER INC.ancers (Vogelstein et al., 2000). To test
hether AMPK signaled to p53 under
ow-glucose conditions, the authors
reated wild-type and p53 null MEFs
ith low glucose, AICAR, or, as a con-
rol, a DNA-damaging dose of γ irradia-
ion (Figure 1). As expected, the p53 null
EFs could not arrest when irradiated.
urprisingly, they also failed to arrest
nder AMPK-activating conditions, sug-
esting that doing so required the stabi-
ization of p53. Along these lines, ex-
ression of CA-AMPK increased levels
f p53. Both observations were in good
greement with earlier work from Ima-
ura and colleagues showing that
ICAR arrested human lung cancer cells
nd induced the expression of many
53-regulated genes (Imamura et al.,
001). An interesting aside is that p53
ull MEFs lost their proliferative advan-
age when glucose was completely re-
oved; in this situation, they were sig-
ificantly less viable than wild-type
EFs.
Many kinases stabilize p53 by phos-
horylation, and it was reasonable to
uspect that AMPK might behave simi-
arly. In fact, p53 contains an N-terminal
erine already known to be targeted by
TM (S15 in humans and S18 in mice)
nd resembling a motif found at the
MPK-directed site of the AMPK target
cetyl-CoA carboxylase (Banin et al.,
998; Canman et al., 1998; Imamura et
l., 2001). Treatment of human 293T
ells with AICAR and cotransfection of
uman H1299 cells with wild-type p53
nd CA-AMPK significantly increased
hosphorylation at this site. Additionally,
he authors showed that immunopreci-
itated myc-tagged AMPK was able to
hosphorylate an N-terminal fragment
f wild-type p53 in vitro but not one
here S18 had been mutated to an ala-
ine. However, it is important to note
hat p53 undergoes many posttransla-
ional modifications, and the contribu-
ion of phosphorylation at S15/S18 in
ivo is not entirely clear (Meek, 1999).287
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Figure 1. AMPK is activated by many forms of metabolic stress, including glucose starvation
AMPK can then induce a cell-cycle arrest by phosphorylating and stabilizing p53, a transcription factor that
1
is also activated by ionizing radiation, UV light, and abberant growth-factor signaling.
I
M
RThis may explain why MEFs carrying a e
eS18A p53 mutant showed an incom-
aplete defect in their ability to arrest when
cAMPK was activated.
tThe finding that glucose starvation
s
causes cell-cycle arrest by activating n
AMPK and p53 adds to our understand- n
ing of how cells handle physiologic h
stresses to key metabolic processes. Al- e
tthough Jones et al. have focused on the288ffects of low glucose, many forms of I
nergetic stress regulate AMPK, and its 1
bility to activate p53 may be a common
Joping mechanism. It will be interesting M
o see if other forms of nutrient stress, C
uch as amino acid deprivation, that are
Mot thought to activate AMPK also sig-
al to p53. A popular hypothesis has V
Neld that tumor cells might gain a prolif-
rative advantage by acquiring muta
ions that permit growth under nutrient Door conditions that cause normal cells
o arrest. The finding that cells lacking
functional p53 continue to proliferate
nder such conditions might be one
ore reason behind the frequency of
53 loss in human cancers. It may also
xplain how the loss of AMPK and LKB1
an promote tumorigenesis.
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